Previous 10 | Next 10 |
home / stock / crpof / crpof news
– First milestone successfully achieved in early stages of the ongoing research project with McMaster University – Confirmed capability of PGX Technology to optimize and standardize the size and morphology of yeast beta-glucan (PGX-YBG) suitable for lung inhalation ...
EDMONTON, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and ...
EDMONTON, Alberta, June 22, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosme...
– Results from successful drug-impregnation of PGX liquid processed alginate hydrogel scaffolds further bolsters Ceapro’s efforts to develop innovative delivery systems composed of new chemical complexes – – Study indicates that PGX-alginate can provide a...
EDMONTON, Alberta, June 09, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF ) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare...
– Maintained production operations during COVID-19 pandemic crisis, providing our customers essential products while ensuring the health and safety of our employees – – R&D activities focused on the development of innovative delivery systems – ...
– New project seeks to expand on positive preliminary results from ongoing research program with McMaster University to develop innovative drug delivery systems using disruptive PGX Technology – Ceapro at the forefront of pioneering approaches with natural products throu...
Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, recently announced operational highlights and financial results for the fourth quarter and full year ende...
The following slide deck was published by Ceapro Inc. in conjunction with this Read more ...
EDMONTON, Alberta, April 16, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO, OTCQX: CRPOF ) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and ...
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...